Immunotech Biopharm (HKSE:06978) Total Assets: HK$666.08 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:06978 Immunotech Biopharm Ltd HKSE:06978
17 GF Score
Price HK$0.39
! 4 Warning Signs
View Full Analysis

What is Immunotech Biopharm Total Assets?

Immunotech Biopharm HKSE:06978 17 Total Assets is HK$666.08 Mil as of Dec. 2025. GuruFocus rates HKSE:06978 with a GF Score™ of 17/100. The stock has 4 warning signs investors should review.

Immunotech Biopharm's Total Assets for the quarter that ended in Dec. 2025 was HK$666.08 Mil.

During the past 12 months, Immunotech Biopharm's average Total Assets Growth Rate was -8.40% per year. During the past 3 years, the average Total Assets Growth Rate was -17.80% per year. During the past 5 years, the average Total Assets Growth Rate was -3.10% per year.

During the past 8 years, Immunotech Biopharm's highest 3-Year average Total Assets Growth Rate was 96.80%. The lowest was -17.80%. And the median was 19.20%.

Total Assets is connected with ROA %. Immunotech Biopharm's annualized ROA % for the quarter that ended in Dec. 2025 was -37.43%. Total Assets is also linked to Revenue through Asset Turnover. Immunotech Biopharm's Asset Turnover for the quarter that ended in Dec. 2025 was 0.00.

Immunotech Biopharm  (HKSE:06978) Total Assets Explanation

Total Assets is connected with ROA %.

Immunotech Biopharm's annualized ROA % for the quarter that ended in Dec. 2025 is

ROA %=Net Income (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=-224.662/( (534.395+666.081)/ 2 )
=-224.662/600.238
=-37.43 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2025) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Immunotech Biopharm's Asset Turnover for the quarter that ended in Dec. 2025 is

Asset Turnover
=Revenue (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=0/( (534.395+666.081)/ 2 )
=0/600.238
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Immunotech Biopharm Total Assets Related Terms

Immunotech Biopharm Total Assets Historical Data

* Premium members only.

The historical data trend for Immunotech Biopharm's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immunotech Biopharm Total Assets Chart

Immunotech Biopharm Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial 1,344.08 982.08 925.65 602.21 666.08

Immunotech Biopharm Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 925.65 774.81 602.21 534.40 666.08
HKSE:06978
17GF Score
Immunotech Biopharm Ltd HKSE:06978
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Immunotech Biopharm Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Immunotech Biopharm's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=-19.008+685.089
=666.08

Immunotech Biopharm's Total Assets for the quarter that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (Q: Dec. 2025 )+Total Liabilities (Q: Dec. 2025 )
=-19.008+685.089
=666.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of HK$666.08 Mil mean?
Immunotech Biopharm (HKSE:06978) has a Total Assets of HK$666.08 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on Immunotech Biopharm and its competitors.
Is Immunotech Biopharm's Total Assets too high?
Immunotech Biopharm's current Total Assets is HK$666.08 Mil. Overall, Immunotech Biopharm has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Immunotech Biopharm's Total Assets compare to VRTX and REGN?
Immunotech Biopharm's Total Assets of HK$666.08 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Immunotech Biopharm and its competitors. Immunotech Biopharm's current Total Assets is HK$666.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunotech Biopharm stock overvalued right now?
Immunotech Biopharm (HKSE:06978) has a current Total Assets of HK$666.08 Mil. The current Total Assets is HK$666.08 Mil. Immunotech Biopharm's overall GF Score™ is 17/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Immunotech Biopharm (HKSE:06978), the current Total Assets is HK$666.08 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Immunotech Biopharm Business Description

Address No.1 Kangding Street, 8th Floor, Block 1, Guosheng Technology Park, Beijing Economic-technological Development Area, Beijing, CHN, 100176
Immunotech Biopharm Ltd is a cellular immunotherapy biopharmaceutical company in China. The company is focused on the research, development, and commercialization of T-cell immunotherapy. Its product EAL is a multi-target cellular immunotherapy product for the treatment of various types of cancer. Its product pipeline features classes of cellular immunotherapy products, including both non-genetically modified and genetically modified products, as well as both multi-target and single-target products. Its other products include the CAR-T cell series and the TCR-T cell series.
17GF Score

Get the complete analysis for HKSE:06978

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.39
Price